Advanced searches left 3/3

Epo - Crossref

Summarized by Plex Scholar
Last Updated: 28 August 2022

* If you want to update the article please login/register

Patenting Procedures and Filing Strategies at the EPO

Abstract This chapter discusses the various routes that can be chosen to obtain patent protection in one or both of the European countries. A typology of four broad filing strategies is created to describe the applicants' behavior: a solid will with fast track, a strong will with slow track, a poor will with slow track, and a deliberate abuse of the system.

Source link: https://doi.org/10.1093/acprof:oso/9780199216987.003.0006


Reservoir Operation Management with New Multi-Objective (MOEPO) and Metaheuristic (EPO) Algorithms

Dam reservoir operation plays a vital role in water quality studies and planning. Basic arithmetic and logical operators modified HR and SOP policies by combining EPO algorithm and Gene Expression Programming with elementary arithmetic and logical operators. Compared to EPOba, the operation rules with EPOad increased the dam reservoir Performance Indexes by an order of magnitude. Also, HR application in comparison to SOP raises the mean dam reservoir's Performance Indexes by 12 and 33% in the baseline and 12 and 21% in the future period, respectively.

Source link: https://doi.org/10.3390/w14152329


Jian-Pi-Yi-Shen Regulates EPO and Iron Recycling Protein Expressions in Anemic Rats with Chronic Kidney Disease: Accumulation of Hypoxia Inducible Factor-2α via ERK Signaling

Abstract Background: The traditional Chinese medicine decoction, Jian-Pi-Shen, has long been used to treat persistent kidney disease and its complications such as anemia. We continue to expand our efforts to investigate the translational control of hypoxia inducible factor - u03b1 protein by ERK signaling and the effect on iron recycling related protein expression by JPYS, thus revealing the mechanism of JPYS in correcting anemia in CKD. Methods: By 5/6 nephrectomy, experimental CKD rats with anemia were induced with anemia. JPYS therapy significantly improved kidney function by lowering elevated levels of blood urea nitrogen, serum creatinine, and urine protein, according to our reports, according to our findings. In both kidney and liver of CKD rats, EPO and HIF-2u03b1 protein expression was boosted by JPYS. In addition, JPYS regulated ferritin and FPN expressions in both liver and spleen of CKD rats, as well as serum levels of hepcidin.

Source link: https://doi.org/10.21203/rs.3.rs-59587/v1


ASXL1 mutations with serum EPO levels predict poor response to darbepoetin alfa in lower-risk MDS: W-JHS MDS01 trial

Abstract Darbepoetin alfa is used to treat anemia in lower-risk myelodysplastic syndromes with anemia. However, whether mutations can predict DA's success has yet to be determined. The present study was designed to identify predictive gene mutations. Overall response rate to DA was 79%. Poorer response was attributed to poor response by erythropoietin levels and red blood cell transfusion numbers, as different results revealed that erythropoietin levels and ASXL1 gene mutations were strongly associated with decreased response. Anemic patients with elevated erythropoietin levels and carriers of ASXL1 gene mutations may have a poor response to DA, according to this report.

Source link: https://doi.org/10.1007/s12185-022-03414-9


Fuzzy-epo Optimization Technique for Optimised Resource Allocation and Minimum Energy Consumption With the Brownout Algorithm.

The VM allocation scheme is used to assign the right number of virtual machines to physical machines. The proposed Fuzzy-EPO algorithm does the VM consolidation mainly to reallocate overloaded VM to under-loaded PM to reduce migration time, but the brownout function is included to reduce energy consumption. The simulation results show that the Fuzzy -EPO based solution is highly effective in reducing the number of SLA offences and raising QoS requirements for providing dependable cloud services.

Source link: https://doi.org/10.21203/rs.3.rs-945687/v1


Epo-IGF1R crosstalk expands stress-specific progenitors in regenerative erythropoiesis and myeloproliferative neoplasm

IGF1R/IRS2 signaling inhibition hinders cell growth in sCFU-E cells, while exogenous IRS2 release promotes cell growth in sCFU-E cells lacking cytoplasmic tyrosines. In myeloproliferative neoplasm patient samples, the number of sCFU-E like cells increases, and the inhibition of IGR1R/IRS2 signaling blocks Epo-hypersensitive erythroid cell colony formation has been reduced. In summary, we describe a new stress-specific erythroid progenitor cell population that links regenerative erythropoeis to pathogenic erythrocytosis. Epo-induced IRS2 promotes involvement of IGF1R, raising a previously unrecognized progenitor population in erythropoietic stress, according to Key Points Epo-induced IRS2 encourages participation of IGF1R signaling to increase a previously unrecognized progenitor population in erythropoietic stress.

Source link: https://doi.org/10.1101/2022.06.27.497649


Relation Between Gender and Concomitant Medications With Erythropoietin-Treatment on Wound Healing in Burn Patients. Post Hoc Subgroup-Analysis of the Randomized, Placebo-Controlled Clinical Trial “EPO in Burns”

u201cEPO in Burns, u201d, placebo-controlled, double-blind, multi-center clinical trial, therefore, was initiated to investigate the effects of EPO versus placebo therapy in severely injured patients. The primary endpoint of u201cEPO in Burns, U201d, was defined as the time elapsed before complete re-epithelialization of a single split skin graft donor site was determined. In terms of the time it took for research wounds to heal the three stages of wound healing, the verum and control groups were compared. For each re-epithelialization rate, the Cox regression model was used to investigate interactions between the study drug and concomitant medications. Using our post hoc identified subgroups, we found a reduced chance of wound healing for women in comparison to men in our study population, regardless of the study's drug use.

Source link: https://doi.org/10.3389/fphar.2022.812888


Abstract 4457: In Search of a novel EPO receptor: The clinical significance of the Eph connection

Recent evidence of poor outcomes among cancer patients receiving Epo increases the fear that Epo could promote tumor formation. We established Ephrin B4 as a novel alternate receptor for Epo given the ambiguity of the erythropoietin receptor in mediating tumor growth stimulatory effects of Epo, we identified it as a novel alternate receptor for Epo. In patients with epithelial ovarian cancer, the current study determines if Epo's clinical effect on prognosis was receptor-dependent. In addition, Epo therapy was correlated to increased mortality among patients with EphB4-overexpressing tumors, but not to patients with elevated tumoral levels of EpoR. Patients with epithelial ovarian cancer have poor results as a result of poor survival among patients with EphB4 (not EpoR) overexpression. Patients with EphB4 overexpressing tumors showed decreased disease-specific patient survival in reduced disease-specific patient survival, according to patient-specific disease.

Source link: https://doi.org/10.1158/1538-7445.am2011-4457


Abstract S5-07: A randomized, open-label, multicenter, phase 3 study of epoetin alfa (EPO) plus standard supportive care versus standard supportive care in anemic patients with metastatic breast cancer (MBC) receiving standard chemotherapy

According to the prescribing data in subjects receiving chemotherapy, no research properly reviewed tumor outcomes when ESAs were used, according to the prescribing findings in patients receiving chemotherapy, but no study rigorously reviewed tumor outcomes. This Phase 3 investigation is the largest MBC trial in patients receiving EPO for chemotherapy-induced anemia specifically designed and conducted to determine progression-free survival as the primary endpoint. Response Evaluation Criteria in Solid Tumors: histologically confirmed MBC, stage IV disease, and at least one concrete metastatic lesion according to Response Evaluation Criteria in Solid Tumors; hemoglobin u226411 g/dL, Eastern Cooperative Oncology Group's performance score 0 or 1. Subjects were randomly assigned to either standard supportive care for anemia treatment of anemia plus 40,000 IU EPO administered subcutaneously every week up to 4 weeks after the last dose of cytotoxic chemotherapy, or SOC alone. Every 8 weeks for the first year and every 12 weeks until disease progression or death, and then every eight weeks until disease progression or death. With a 1-sided Type I error rate 0. 025, a sample size of 1,650 disease progression or death events was determined to rule out a 15% hazard rate rise in PFS. [abstract]: A multicenter, phase 3 research of epoetin alfa plus standard supportive care in anemic breast cancer patients receiving standard chemotherapy [abstract]. San Antonio, Texas, October 9-13, Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium.

Source link: https://doi.org/10.1158/1538-7445.sabcs14-s5-07


Abstract 3464: The effect of EPO-receptor in estrogen receptor positive breast cancer

Breast cancer tissue and cells are shown to have the EPOR protein in both breast cancer tissue and cells using a recently manufactured anti-EPOR antibody that easily detects the EPOR full-length isoform of the EPOR. However, EPOR knockdown experiments demonstrated functional EPO receptors in estrogen receptor positive breast cancer cells, as reduced EPOR expression resulted in decreased proliferation. On Ser118, results that further support a mechanism by which EPOR knockdown reduces ER0b1 activity in ER+ breast cancer cells and reduced ER0b1+ phosphorylation, which could help with a mechanism by which EPOR promotes proliferation by ER-u03b1+ mediated mechanisms. In part, we find that EPOR protein is expressed in breast cancer cells, where it may promote proliferation in ERu03b1+ expressing breast cancer cells, in part due to its ability to positively influence ER-u03b1 activity.

Source link: https://doi.org/10.1158/1538-7445.am2014-3464

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions